Aviron FluMist Initial Indication May Exclude Youngest Children, CEO Says
Executive Summary
Aviron is willing to change the proposed pediatric indication for its intranasal flu vaccine FluMist if that would hasten FDA approval, CEO Boyd Clarke told analysts July 30.
You may also be interested in...
Lilly Forteo Follow-Up Rat Osteosarcoma Study To Finish By End Of 2002
Lilly's follow-up Forteo (teriparatide) osteosarcoma study is expected to be completed by the end of 2002, FDA told the Endocrinologic and Metabolic Drugs Advisory Committee July 27.
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Approval of Wyeth/Aviron's intranasal flu vaccine FluMist will likely hinge on further analysis of the pulmonary safety data for the product and information about interactions with concurrent immunizations following a review by FDA's Vaccines & Related Biological Products Advisory Committee July 27.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011